Clinical characteristics and outcomes of macrolide-resistant

Guiju Li, Lei Zhang, Yijie Huang, Meimei Lai

Abstract read

In one paragraph

Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Prediction of atelectasis inFrontiers in pediatrics · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Guiju Li *Department of Paediatric, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

Lei Zhang *Department of Paediatric, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

Yijie HuangDepartment of Paediatric Pulmonology, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

Meimei LaiDepartment of Laboratory, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The rising global prevalence of macrolide-resistant Methods: In this single-center, retrospective cohort study, 175 pediatric patients hospitalized with MPP between February 2023 and May 2024 were enrolled. Patients were divided into an MRMP group (n=95) and a non-MRMP group (n=80) based on 23S rRNA gene mutations detected in Results: The prevalence of MRMP was 54.3% (95/175), with all strains carrying the A2063G mutation. Compared to the non-MRMP group, MRMP patients had significantly higher rates of lung consolidation (74.7% Conclusions: MRMP infection in children is associated with more severe pulmonary and extrapulmonary manifestations and a higher risk of progressing to RMPP. The developed prediction model, utilizing easily obtainable clinical parameters, demonstrates high diagnostic accuracy for early identification of RMPP risk, potentially facilitating timely intervention and improving patient outcomes.

Indexed as

clinical characteristicsmacrolide-resistant Mycoplasma pneumoniae (MRMP)Mycoplasma pneumoniaerefractory Mycoplasma pneumoniae pneumonia (RMPP)risk factors

Identifiers

PMID41216450

DOI10.21037/tp-2025-290

PMCPMC12597172

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.